Chun Felix K-H, Briganti Alberto, Lebeau Thierry, Fradet Vincent, Steuber Thomas, Walz Jochen, Schlomm Thorsten, Eichelberg Christian, Haese Alexander, Erbersdobler Andreas, McCormack Michael, Perrotte Paul, Graefen Markus, Huland Hartwig, Karakiewicz Pierre I
Cancer Prognostics and Health Outcomes Unit and the Department of Urology, University of Montreal Health Center, Montreal, Canada.
Eur Urol. 2006 Feb;49(2):273-8; discussion 278-9. doi: 10.1016/j.eururo.2005.12.009. Epub 2006 Jan 6.
We examined the prognostic value of AJCC pT2 substages in prediction of biochemical recurrence (BCR) after radical prostatectomy (RP), in European patients.
A cohort of 1726 RP patients with pT2N0 prostate cancer (PCa) was studied. Multivariate Cox regression models addressed the association between either the 1997 or 1992/2002 pT2 substages after controlling for total PSA, primary and secondary pathologic Gleason scores and surgical margin status and time to PSA recurrence (PSA >0.1 and rising) after RP. Regression coefficients were then used to test the predictive accuracy of multivariate models in a nomogram setting.
PSA recurrence occurred in 80 (4.6%) patients. Mean and median times to recurrence were respectively 28.9 and 24.4 months. In univariate analyses, neither the 1997 (p = 0.48) nor the 1992/2002 pT2 substages (p = 0.054) were predictive of recurrence. In multivariate analyses the lack of significance persisted (1997 p = 0.709; 1992/2002 p = 0.124). When either the 1997 or 1992/2002 pT2 substages were added to a multivariate nomogram without pT2 substage information, its accuracy respectively decreased by 0.8% and 1.1%.
Our data indicate that pT2 substages offer no incremental value relative to pre-treatment total PSA, surgical margin status and pathologic Gleason scores. Therefore, it might be postulated that it is sufficient to confirm organ confinement according to Partin's pathologic staging.
我们研究了美国癌症联合委员会(AJCC)pT2亚分期对欧洲患者根治性前列腺切除术(RP)后生化复发(BCR)的预测价值。
研究了1726例pT2N0前列腺癌(PCa)的RP患者队列。多变量Cox回归模型在控制总前列腺特异抗原(PSA)、原发和继发病理Gleason评分、手术切缘状态以及RP后PSA复发时间(PSA>0.1且呈上升趋势)后,探讨1997年或1992/2002年pT2亚分期之间的关联。然后使用回归系数在列线图设置中测试多变量模型的预测准确性。
80例(4.6%)患者出现PSA复发。复发的平均时间和中位时间分别为28.9个月和24.4个月。在单变量分析中,1997年(p=0.48)和1992/2002年pT2亚分期(p=0.054)均不能预测复发。在多变量分析中,这种无显著性的情况仍然存在(1997年p=0.709;1992/2002年p=0.124)。当将1997年或1992/2002年pT2亚分期添加到无pT2亚分期信息的多变量列线图中时,其准确性分别降低了0.8%和1.1%。
我们的数据表明,相对于治疗前总PSA、手术切缘状态和病理Gleason评分,pT2亚分期没有额外价值。因此,可以推测根据帕廷病理分期确认器官局限性就足够了。